Galapagos (NASDAQ:GLPG) Given Underweight Rating at Barclays

Barclays reissued their underweight rating on shares of Galapagos (NASDAQ:GLPG) in a research note issued to investors on Thursday morning,Benzinga reports.

Several other equities analysts also recently weighed in on the company. Kepler Capital Markets downgraded Galapagos from a “hold” rating to a “reduce” rating in a research report on Wednesday, November 20th. Royal Bank of Canada cut their price objective on shares of Galapagos from $32.00 to $30.00 and set a “sector perform” rating on the stock in a research report on Friday, November 1st. Finally, TD Cowen lowered shares of Galapagos from a “strong-buy” rating to a “strong sell” rating in a report on Thursday, January 9th. Four investment analysts have rated the stock with a sell rating and six have assigned a hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $30.75.

Galapagos Price Performance

Shares of NASDAQ GLPG opened at $23.74 on Thursday. Galapagos has a 1-year low of $23.45 and a 1-year high of $40.34. The business’s 50 day moving average is $26.70 and its two-hundred day moving average is $27.45.

Institutional Trading of Galapagos

A number of large investors have recently made changes to their positions in the stock. R Squared Ltd bought a new stake in Galapagos during the 4th quarter valued at about $26,000. Crossmark Global Holdings Inc. increased its position in shares of Galapagos by 31.5% during the fourth quarter. Crossmark Global Holdings Inc. now owns 49,163 shares of the biotechnology company’s stock worth $1,352,000 after acquiring an additional 11,777 shares during the period. GAMMA Investing LLC raised its stake in shares of Galapagos by 77.4% during the fourth quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 974 shares in the last quarter. Erste Asset Management GmbH purchased a new stake in shares of Galapagos in the third quarter valued at approximately $410,000. Finally, Finepoint Capital LP grew its stake in Galapagos by 2.8% in the third quarter. Finepoint Capital LP now owns 557,762 shares of the biotechnology company’s stock worth $16,058,000 after purchasing an additional 15,000 shares in the last quarter. 32.46% of the stock is owned by hedge funds and other institutional investors.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.